How India Exports Gutika to the World

As of March 2026, "Gutika" (HS Code: 30049011) does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. This indicates that no generic versions of this product have been approved for marketing in the United States. Additionally, there are no recent approvals or import alerts related to "Gutika" recorded by the FDA.

Given the absence of approved ANDAs and the lack of import alerts, the regulatory pathway for "Gutika" in the U.S. remains undefined. This presents an opportunity for Indian exporters to explore the U.S. market, considering the product's current export value of $0.1 million USD and the involvement of 56 active Indian exporters.

In the European Union and the United Kingdom, "Gutika" is not listed among the medicines with marketing authorizations granted by the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This suggests that the product has not undergone the centralized approval process required for marketing in these regions.

To obtain marketing authorization in the EU and UK, "Gutika" would need to comply with Good Manufacturing Practice (GMP) requirements as stipulated by the EMA and MHRA. This includes adherence to quality standards in manufacturing processes, facilities, and product testing to ensure safety and efficacy.

"Gutika" is not included in the World Health Organization's (WHO) Model List of Essential Medicines, which is periodically updated to reflect global health priorities. Additionally, there is no record of "Gutika" undergoing the WHO Prequalification Programme, a service that assesses the quality, safety, and efficacy of medicinal products.

Regarding pharmacopoeial standards, "Gutika" does not appear in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP). This absence indicates that the product has not been standardized according to these internationally recognized compendia.

In India, "Gutika" is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug requiring a doctor's prescription for dispensation. As of March 2026, the National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for "Gutika," allowing market forces to determine its pricing.

For export purposes, Indian manufacturers of "Gutika" must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT). This certificate ensures compliance with export regulations and verifies that the product meets the necessary quality standards for international markets.

As of March 2026, "Gutika" does not have any active patents or exclusivity rights listed in major patent databases. This lack of patent protection suggests that there are no legal barriers to generic competition, potentially allowing multiple manufacturers to produce and market the product without infringing on intellectual property rights.

In June 2025, the Indian Ministry of Health and Family Welfare introduced new guidelines aimed at enhancing the quality standards for pharmaceutical exports. These guidelines emphasize stricter compliance with Good Manufacturing Practices (GMP) to ensure the safety and efficacy of exported medicines.

In September 2025, the World Health Organization (WHO) updated its Model List of Essential Medicines, adding several new treatments for non-communicable diseases. While "Gutika" was not included in this update, the revision reflects the WHO's ongoing efforts to address global health challenges.

In December 2025, the European Medicines Agency (EMA) implemented revised guidelines for the assessment of herbal medicinal products. These guidelines aim to streamline the approval process for herbal medicines, potentially impacting products like "Gutika" seeking entry into the European market.

In February 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance document outlining the regulatory framework for combination products that include both drug and device components. This guidance provides clarity on the approval process for such products, which may be relevant for complex formulations similar to "Gutika."

In March 2026, the Indian government announced a reduction in export duties for certain pharmaceutical products to boost international trade. This policy change is expected to benefit exporters of "Gutika" by making the product more competitive in global markets.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API requirements are fulfilled by Chinese manufacturers. This dependency exposes the supply chain to significant risks, as any disruption in Chinese production or export policies can lead to shortages and price volatility in the Indian pharmaceutical sector.

The COVID-19 pandemic underscored these vulnerabilities when Chinese factory shutdowns led to immediate scarcities of essential APIs, causing price surges for common medications. The situation highlighted the critical need for India to bolster its domestic API and KSM production capabilities to mitigate such risks in the future.

Our proprietary trade data indicates that the top five exporters of "Gutika" from India account for 63.5% of total exports, with DABUR INDIA LIMITED leading at a 25.9% share. This high supplier concentration poses a single-source risk; any operational or regulatory issues affecting these key exporters could disrupt the supply chain.

To address such dependencies, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to reduce reliance on imports by promoting domestic manufacturing of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and 6-APA, marking a significant step toward self-sufficiency.

Recent geopolitical tensions have further strained global supply chains. The closure of the Strait of Hormuz in February 2026, following military conflicts, disrupted the movement of oil and other critical goods, including pharmaceuticals. This blockade led to increased shipping costs and delays, impacting the timely delivery of pharmaceutical products.

Additionally, the Red Sea and Suez Canal have experienced instability due to regional conflicts, compelling shipping companies to reroute vessels around Africa's Cape of Good Hope. This detour adds significant transit time and costs, further complicating the logistics of pharmaceutical exports from India.

• Diversify Supplier Base: Expand the network of API and KSM suppliers beyond China to include other countries and bolster domestic production capabilities.

• Enhance Domestic Manufacturing: Leverage government initiatives like the PLI scheme to invest in local API and KSM production facilities, reducing import dependence.

• Strengthen Supply Chain Resilience: Develop strategic reserves of critical raw materials and establish contingency plans to manage potential disruptions.

• Monitor Geopolitical Developments: Stay informed about international conflicts and shipping lane statuses to proactively adjust logistics strategies.

• Invest in Advanced Manufacturing Technologies: Adopt innovative manufacturing processes to improve efficiency and reduce costs, making domestic production more competitive.

RISK_LEVEL: MEDIUM